Compare Asana Inc. (ASAN) vs AstraZeneca plc (AZN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Asana Inc. vs AstraZeneca plc — how do they compare? Asana Inc. trades at $9.16 (market cap $2.13B), while AstraZeneca plc trades at $158.4 (market cap $248.14B). The key difference: AstraZeneca plc is far larger — about 116.5× Asana Inc.'s market cap, and AstraZeneca plc pays a 2.01% dividend while Asana Inc. pays none. Which is the better fit depends on your goals.
| ASAN | AZN | |
|---|---|---|
Market Cap | $2.13B | $248.14B |
Sector | Consumer Cyclical | Health |
52-Week High | $15.19 | $209.48 |
52-Week Low | $5.46 | $147.06 |
Enterprise Value | $1.96B | $275.41B |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Asana (ASAN) trades at $9.065, down 1.79% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Revenue growth is strong, reaching $723.88M in 2025, yet the company remains unprofitable with a net income margin of -20.21%. Recent earnings beats and AI product developments, including the StackAI acquisition, highlight operational momentum amid competitive pressures.
The outlook is mixed: analyst consensus leans neutral with a $10.33 price target, suggesting modest upside, but persistent losses and high valuation ratios pose risks. Key catalysts include continued AI integration and FedRAMP authorization, while decelerating revenue growth and competition from tech giants remain headwinds for shareholder value.
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Asana Inc.
Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives. It helps plan marketing campaigns, streamlines processes, manages sales, and manage product launches. Also, the company provides project management and workflow management solutions.
Read more on ASAN →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
